Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019783 · ClinicalTrials.gov registry record · Phase 2
Atazanavir and Endothelial Function in Older HIV Patients
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT03019783 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 60 participants.
The verdict
NCT03019783, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The investigators hypothesize that older subjects with HIV randomly assigned to atazanavir will have increased bilirubin levels, reduced oxidative stress, and improved flow-mediated, endothelium-dependent vasodilation compared to subjects not switched to atazanavir.
Interventions
- OTHER Placebo
- DRUG Atazanavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03019783
The ClinicalTrials.gov registry entry for NCT03019783 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03019783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03019783 about?
NCT03019783 is a clinical study titled "Atazanavir and Endothelial Function in Older HIV Patients". The investigators hypothesize that older subjects with HIV randomly assigned to atazanavir will have increased bilirubin levels, reduced oxidative stress, and improved flow-mediated, endothelium-dependent vasodilation compared to subjects not switched to atazanavir.
What is the current status of trial NCT03019783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT03019783?
The interventions under investigation include: Placebo (OTHER), Atazanavir (DRUG).
Who is sponsoring clinical trial NCT03019783?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.